Industry News
Pharmaceutical Industry News
Based in Poland, biologics-focused…
Based in Poland, biologics-focused CDMO Rezon Bio announced its launch on the European contracting scene Monday. The company plans to use its biosimilars know-how to make development and commercialization processes simple and straightforward for partners.
The results, coupled with a prior…
The results, coupled with a prior win, could set up Enhertu to be a "foundational treatment option” in the curative-intent breast cancer setting, AstraZeneca and Daiichi Sankyo said.
Kedrion Biopharma has scored an…
Kedrion Biopharma has scored an FDA approval for Qivigy, a treatment for adults with primary humoral immunodeficiency (PI). Along with the nod, the Italian company announced plans to boost its investment in the United States.
Elawadhi points to predictive AI…
Elawadhi points to predictive AI and regulations as drivers of smarter, more personalized engagement.
In laying out their respective…
In laying out their respective plans Monday to launch new direct-to-patient platforms paring down the prices of popular medicines in the U.S., Novartis and Boehringer Ingelheim are falling in line with demands from President Donald
In a bid to “harmonize its share…
In a bid to “harmonize its share listing structure,” AstraZeneca aims to list its shares directly on the New York Stock Exchange. While AZ will continue to trade on the London Stock Exchange and retain
As pharma companies work to…
As pharma companies work to respond to President Donald Trump's drug pricing demands, PhRMA is touting three "major actions" by its members and calling for some policy shifts of its own.
The first woman to take the helm…
The first woman to take the helm of any Big Pharma is stepping down in January as GSK’s chief Emma Walmsley will move aside for her chief commercial officer Luke Miels.
How Trump’s Latest Tariffs May Affect Your Medicines
The president said he would impose a tariff of 100 percent on certain brand-name drugs. Here’s what we know so far.
Trump’s Pharma Tariffs Spare Richest Drugmakers
The details of the president’s proposed tariffs were not clear. But it seemed that many big companies would qualify for exemptions.
Trump Expands Tariffs Beyond Supreme Court’s Reach
The president’s tariffs on foreign drugs and furniture rely on national security laws outside the scope of current lawsuits.
Jeff Keller discusses technology,…
Jeff Keller discusses technology, stakeholder needs and evolving pharma roles
Kristin Cahill says industry must…
Kristin Cahill says industry must focus on impact over vanity metrics
Focus on personalization,…
Focus on personalization, people-based data and patient context driving change
Wary European Drugmakers Think They Can Avoid Trump’s Latest Tariffs
European companies, a major source of U.S. medicines, are hopeful that their investments and trade deals with the U.S. will spare them from President Trump’s latest tariff barrage.
Spectrum Science’s Michelle…
Spectrum Science’s Michelle Gross on translating innovation into impact
In an expansion of its previous…
In an expansion of its previous moves to cut the price of insulin in the U.S., Sanofi now will cap the price for all of its insulin products at $35 per month regardless of a
AstraZeneca is the latest Big…
AstraZeneca is the latest Big Pharma to unveil a digital direct-to-consumer platform offering certain medicines at heavily reduced prices to cash-pay patients.
Amgen has spent the last three…
Amgen has spent the last three decades building out its presence in Puerto Rico. With a $650 million investment revealed Friday, the company's site in Juncos is set to grow again.
The 100% rate floated in Donald…
The 100% rate floated in Donald Trump’s new communique on pharmaceutical tariffs may appear steep, but the reality of the situation is likely less severe than it seems, multiple analysts wrote Friday following the president’s